MGMikhail F. Gordeev

Mikhail F. Gordeev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mikhail F. Gordeev has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A survival analysis of patients after bioprosthetic aortic valve replacement using machine learning methods

    by A. D. Maistrenko, V. V. Kurashenko, V. E. Uspensky, A. V. Gurshchenko, D. T. Keremov, P. S. Mkhitaryan, M. L. Gordeev

    Aim. To evaluate the long-term survival of patients after bioprosthetic aortic valve replacement and compare the prognostic capabilities of the classical Cox model and the Random Survival Forest (RSF) algorithm, including the interpretation of the contribution of clinical variables. Material and methods. The study included 176 patients who underwent aortic valve replacement at the Almazov National Medical Research Center from 2015 to 2024. Clinical, laboratory, echocardiographic, and intraoperative characteristics were assessed. Survival analysis was performed using the Cox proportional hazards model and the RSF algorithm. The C-index was used to assess the accuracy of the models. A SHAP analysis of traits’ contribution of RSF model was also performed. The primary endpoint was all-cause mortality. Secondary endpoints were complications and readmissions. Results . The Cox model demonstrated moderate predictive accuracy (C-index 0,72), allowing for the identification of following significant risk factors: atrial fibrillation, low hemoglobin, elevated creatinine, older age, and reduced ejection fraction. The RSF algorithm demonstrated higher accuracy (C-index 0,86) and successful risk stratification as follows: 5-year survival was 95,3% in the low-risk group, 77,6% in the intermediate-risk group, and 59,7% in the high-risk group. SHAP analysis confirmed the influence of these parameters and also demonstrated the role of body mass index, sex, and heart failure functional class. Conclusion. The RSF algorithm demonstrated greater prediction accuracy compared to the Cox model and enabled more flexible and interpretable risk stratification.

  • Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies

    by Jinqian Liu, Wen Wang, Changqing Wang, Li Zhang, Xueliang Zhang, Shicong Liu, Yunhua Xu, Hailin Wang, Qing Dai, Chun Liu, et al.

    New oral antibiotic contezolid (CZD) is effective against Gram-positive infections but unsuitable for intravenous (IV) administration due to its modest solubility. To address the medical need for an IV form of CZD, its isoxazol-3-yl phosphoramidate derivatives have been explored, and contezolid acefosamil (CZA, 8), the first representative of a novel O-acyl phosphoramidate prodrug class, has been identified. CZA exhibits high aqueous solubility (>200 mg/mL) and good hydrolytic stability at media pH suitable for IV administration. CZA rapidly converts into the active drug CZD in vivo. In a pharmacokinetic (PK) rat model, the exposure of active drug CZD after IV administration of the prodrug CZA was similar to or higher than that from the IV administration of CZD. The prodrug CZA is bioequivalent to or better than CZD in several preclinical infection models. CZA is likewise active upon its oral administration. To date, CZA has been evaluated in Phase 1 and Phase 2 clinical trials in the USA. It is advancing into further clinical studies including step-down therapy with in-hospital intravenous CZA administration followed by outpatient oral CZD treatment.


  • Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity

    by Wen Wang, Kate M. Voss, Jinqian Liu, Mikhail F. Gordeev

    Linezolid, the principal oxazolidinone antibiotic for therapy of Gram-positive infections, is limited by its myelosuppression and monoamine oxidase (MAO) inhibition, with the latter manifested as serotonergic neurotoxicity. The oral oxazolidinone contezolid and its injectable prodrug contezolid acefosamil are developed to overcome the above limitations. Serotonergic profiles for contezolid in vitro and for orally administered contezolid acefosamil in rodents are reported. Contezolid exhibited 2- and 148-fold reduction over linezolid reversible inhibition of MAO-A and MAO-B human enzyme isoforms. In the mouse head-twitch model, contezolid acefosamil was devoid of neurotoxicity at supratherapeutic oral doses of 40, 80, and 120 mg/kg. In the rat tyramine challenge model, no significant increase in arterial blood pressure was observed for contezolid acefosamil up to 120 mg/kg oral dosing. In these tests, the comparator linezolid has elicited serotonergic responses. Thus, contezolid and contezolid acefosamil exhibited an attenuated propensity to induce MAO-related serotonergic neurotoxicity. The data support a continued clinical evaluation of these agents, with potential to expand oxazolidinone therapies to patient populations on concurrent selective serotonin reuptake inhibitor medications or where MAO inhibitors are contraindicated.


  • New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile

    by Mikhail F. Gordeev, Zhengyu Y. Yuan

    Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors. Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid. This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), distinguished by its high activity against Gram-positive pathogens coupled with markedly reduced potential for myelosuppression and MAOI. The medical need, medicinal chemistry rationale, preclinical data, and phase I clinical trial summary for this new agent are reviewed herein.


  • Open Access

    Synthesis of Aza‐, Oxa‐, and Thiabicyclo[3.1.0]hexane Heterocycles from a Common Synthetic Intermediate.

    by Adam R. Renslo, Hongwu Gao, Priyadarshini Jaishankar, Revathy Venkatachalam, Mikhail F. Gordeev

    For Abstract see ChemInform Abstract in Full Text.

  • ChemInform Abstract: New 1H‐Benzotriazole‐Mediated Synthesis of N,N′‐Disubstituted Thioureas and Carbodiimides.

    by A. R. Katritzky, M. F. Gordeev

    ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.